Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$77.75 USD

77.75
1,349,517

+1.08 (1.41%)

Updated Jul 10, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

by Kinjel Shah

While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.

Novo Nordisk (NVO) to Buy Cardior to Boost Heart Disease Pipeline

by Zacks Equity Research

Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals for 1.025 billion euros to establish a presence in cardiovascular disease.

AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication

by Zacks Equity Research

FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.

Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

In the latest trading session, Astrazeneca (AZN) closed at $65.86, marking a -0.6% move from the previous day.

Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?

by Zacks Equity Research

Ionis' (IONS) collaboration revenues enable it to invest in its wholly-owned pipeline. This is expected to enhance Ionis' already diverse revenue streams.

Kinjel Shah headshot

Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates

by Kinjel Shah

AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.

Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study

by Zacks Equity Research

Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.

GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US

by Zacks Equity Research

GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.

Fusion (FUSN) Up 99% on $2.4B Buyout Offer From AstraZeneca

by Zacks Equity Research

AstraZeneca (AZN) is set to acquire Fusion Biopharma (FUSN) for $21 per share in cash, along with a contingent value right of $3 per share, tied to a regulatory milestone.

AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B

by Zacks Equity Research

AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.

Astrazeneca (AZN) Rises Yet Lags Behind Market: Some Facts Worth Knowing

by Zacks Equity Research

Astrazeneca (AZN) closed at $65.86 in the latest trading session, marking a +0.02% move from the prior day.

AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US

by Zacks Equity Research

AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More

by Kinjel Shah

AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.

AstraZeneca (AZN) to Acquire Amolyt Pharma for $1.05 Billion

by Zacks Equity Research

AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide.

Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts

by Zacks Equity Research

Astrazeneca (AZN) reachead $67.58 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.

Pharma Stock Roundup: NVO's New Obesity Pill Data, RHHBY, AZN's Pipeline Updates

by Zacks Equity Research

Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.

Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

Astrazeneca (AZN) closed the most recent trading day at $66.19, moving +1.41% from the previous trading session.

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.

The Zacks Analyst Blog Highlights Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International

by Zacks Equity Research

Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Costco, Walt Disney & AstraZeneca

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN).

Kinjel Shah headshot

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

by Kinjel Shah

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively